Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €9.50 EUR
Change Today -0.094 / -0.98%
Volume 0.0
ITH On Other Exchanges
As of 12:43 PM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

nektar therapeutics (ITH) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/15 - €13.64
52 Week Low
08/24/15 - €8.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEKTAR THERAPEUTICS (ITH)

nektar therapeutics (ITH) Related Businessweek News

No Related Businessweek News Found

nektar therapeutics (ITH) Details

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology. The company offers MOVANTIK, an oral peripherally-acting mu-opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives. Its drug candidates in clinical development stage comprises BAX 855 that is in Phase III clinical trial for treating Hemophilia A; BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-181 that is in Phase III clinical trial for chronic pain; NKTR-171, which is in Phase I clinical trial to treat neuropathic pain; and NKTR-214 that is in research and preclinical trial stage to treat oncology, as well as MOVANTIK, which is research and preclinical stage for treating chronic pain without constipation. The company’s drug candidates in clinical development stage also include etirinotecan pegol, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as has completed Phase II clinical trial stage for platinum-resistant/refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat gastrointestinal-related solid tumors, which has completed Phase I clinical trial. Nektar Therapeutics has collaboration with Baxter Healthcare; Bayer Healthcare LLC; and AstraZeneca AB. In addition, it has license, manufacturing, and supply agreements with Amgen Inc.; Allergan, Inc.; Halozyme Therapeutics, Inc.; Merck & Co., Inc.; Ophthotech Corporation; Pfizer, Inc.; F. Hoffmann-La Roche Ltd (Roche); and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.

438 Employees
Last Reported Date: 02/26/15
Founded in 1990

nektar therapeutics (ITH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $860.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $542.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $526.1K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $477.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $372.7K
Compensation as of Fiscal Year 2014.

nektar therapeutics (ITH) Key Developments

Nektar Therapeutics Closes Direct Private Placement with TPG Special Situations Partners of $250 Million of Senior Secured Notes Due in 2020

Nektar Therapeutics announced the closing of a direct private placement of $250 million of 7.75% senior secured notes due in 2020 with investment vehicles managed by affiliates of TPG Special Situations Partners, the dedicated special situations and credit platform with over $12 billion of assets under management, and part of TPG, a leading global private investment firm. Nektar used a portion of the proceeds from the 7.75% senior secured notes to redeem all of its currently outstanding $125 million of 12.0% senior secured notes due in 2017. The 7.75% notes are callable by Nektar beginning in October 2017, subject to certain prepayment premiums and conditions. The senior secured notes are not subject to financial performance targets. The offer and sale of the notes is exempt from the registration requirements of the Securities Act of 1933. For further details on the terms and conditions of the senior secured notes.

Nektar Therapeutics Announces Positive Preclinical Results for NKTR-214

Nektar Therapeutics announced positive preclinical results for NKTR-214, a CD122-biased cytokine designed to preferentially stimulate the production and maintenance of tumor-killing T cells which are found naturally in the body. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase the proliferation of CD8-positive effector T cells, and these CD8-positive T cells comprise a key component of the tumor infiltrating lymphocytes that provide cell-mediated anti-tumor effects. Combination regimens with NKTR-214 and either anti-CTLA4 or anti-PD-1 checkpoint inhibitor therapies resulted in durable anti-tumor immunotherapeutic effects, which persisted long after the termination of dosing. In a preclinical tumor re-challenge study presented, sequential dosing of anti-CTLA-4 followed by NKTR-214 resulted in durable and complete responses. At 142 days following the final dose, with no additional treatment, the complete responders demonstrated sustained resistance to multiple tumor re-challenges. In highly-resistant established melanoma tumor models, data presented show that treatment with NKTR-214 resulted in a controlled, sustained and biased T-cell activating signal and a mean ratio of CD8-positive T cells to T-regulatory cells ratio of 450:1 in the tumor infiltrating lymphocytes.

Nektar Therapeutics - Analyst/Investor Day

To present an overview of the company's pain and oncology portfolio


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ITH:GR €9.50 EUR -0.094

ITH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $18.79 USD -0.08
Emergent BioSolutions Inc $29.92 USD -0.66
Ironwood Pharmaceuticals Inc $10.72 USD -0.43
Sucampo Pharmaceuticals Inc $18.69 USD +0.29
Theravance Inc $7.97 USD -0.37
View Industry Companies

Industry Analysis


Industry Average

Valuation ITH Industry Range
Price/Earnings 100.0x
Price/Sales 5.1x
Price/Book 41.8x
Price/Cash Flow 241.2x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at